Clinical trial
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With…
NCT00438204 · Barbara Ann Karmanos Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00438204 |
|---|---|
| Title | Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients With Stages IIIB/IV Non- Squamous, Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, gemcitabine hydrochloride, pemetrexed disodium |
| Enrollment | 39 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2013 |
| Completion | Jun 1, 2016 |
| First posted | Feb 22, 2007 |
| Last update posted | Apr 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: